Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sanofi - Aventis Groupe

< Previous 1 2 3 4 Next >
Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the Q2 2023 Memorandum for modelling purposes
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi completes acquisition of Provention Bio, Inc.
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the Q1 2023 Memorandum for modelling purposes
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A
From Sanofi - Aventis Groupe
Via GlobeNewswire
ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi announces change in R&D leadership
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release:  Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.